ArticleBritish journal of cancer2025
Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study.
Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing YOLOv11 for automated classification of breast cancer in medical images.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTo develop and test a relation knowledge distillation three-dimensional residual network (RKD-R3D) model for predicting breast cancer molecular subtypes using ultrasound (US) videos to aid clinical personalized management.
methodsThis multicentre study retrospectively included 882 breast cancer patients (2375 US videos and 9499 images) between January 2017 and December 2021, which was divided into training, validation, and internal test cohorts. Additionally, 86 patients was collected between May 2023 and November 2023 as the external test cohort. St. Gallen molecular subtypes (luminal A, luminal B, HER2-positive, and triple-negative) were confirmed via postoperative immunohistochemistry. The RKD-R3D based on US videos was developed and validated to predict four-classification molecular subtypes of breast cancer. The predictive performance of RKD-R3D was compared with RKD-R2D, traditional R3D, and preoperative core needle biopsy (CNB). The area under the receiver operating characteristic curve (AUC), sensitivity, specificity, accuracy, balanced accuracy, precision, recall, and F1-score were analyzed.
resultsRKD-R3D (AUC: 0.88, 0.95) outperformed RKD-R2D (AUC: 0.72, 0.85) and traditional R3D (AUC: 0.65, 0.79) in predicting four-classification breast cancer molecular subtypes in the internal and external test cohorts. RKD-R3D outperformed CNB (Accuracy: 0.87 vs. 0.79) in the external test cohort, achieved good performance in predicting triple negative from non-triple negative breast cancers (AUC: 0.98), and obtained satisfactory prediction performance for both T1 and non-T1 lesions (AUC: 0.96, 0.90).
conclusionsRKD-R3D when used with US videos becomes a potential supplementary tool to non-invasively assess breast cancer molecular subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.